PI3K/Akt信号通路作为微孢子虫性角膜基质炎抗炎与抗基质损伤的潜在治疗靶点
该研究在小鼠微孢子虫性角膜基质炎(MSK)模型中,通过转录组分析、RT-qPCR、免疫染色和蛋白磷酸化检测发现感染明显激活角膜PI3K/Akt通路并上调MMP9、IL-1β、TNF-α等炎症因子。结膜下注射PI3K/Akt抑制剂LY294002预处理可减轻角膜混浊等临床表现并降低角膜炎症因子表达,提示靶向该通路可能成为MSK的治疗策略。
要点
- 微孢子虫感染可明显激活角膜PI3K/Akt通路并上调炎症因子表达。
- 结膜下注射LY294002预处理可减轻MSK小鼠角膜混浊等临床表现。
- PI3K/Akt通路是MSK炎症的关键驱动因素,或为潜在治疗靶点。
核心结论
- PI3K/Akt信号通路是微孢子虫性角膜基质炎炎症的关键驱动因素。
- 靶向PI3K/Akt通路可能为MSK的管理提供有前景的策略。
研究设计与样本
- 建立小鼠微孢子虫性角膜基质炎模型,并进行转录组分析以识别感染后的基因表达变化。
- 通过RT-qPCR、免疫染色和蛋白磷酸化检测评估PI3K/Akt通路的激活情况。
- 通过结膜下注射PI3K/Akt抑制剂LY294002,评估其对感染过程中角膜炎症和细胞因子产生的影响。
主要发现
- 微孢子虫感染使角膜中PI3K和Akt磷酸化增加,明显激活PI3K/Akt通路。
- 转录组分析显示MMP9、IL-1β和TNF-α等炎症细胞因子上调,提示炎症相关通路激活。
- 组织学分析证实感染角膜中免疫细胞浸润增加和基质水肿。
- 感染前使用LY294002预处理可减轻MSK临床表现(包括角膜混浊),并降低角膜炎症表达水平。
临床怎么用
- PI3K/Akt通路可作为MSK抗炎和减轻角膜基质损伤的潜在干预靶点。
- 未来需开发眼用优化的PI3K/Akt通路抑制剂并评估其安全性和疗效。
局限性
- 研究结论主要基于小鼠模型和LY294002预处理,尚未在临床MSK患者中验证。
- 眼用优化的PI3K/Akt抑制剂的安全性和疗效尚待未来研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the role of the PI3K/Akt pathway in microsporidial stromal keratitis (MSK) and evaluate whether targeted inhibition of this pathway could provide a potential therapeutic strategy. METHODS: A mouse model of MSK was established, followed by transcriptomic analysis to identify gene-expression changes following microsporidial infection. The activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was assessed through real-time quantitative polymerase chain reaction (RT-qPCR), immunostaining, and protein phosphorylation assays. To explore therapeutic implications, the PI3K/Akt inhibitor LY294002 was administered by subconjunctival injection, and its effects on corneal inflammation and cytokine production were assessed over the course of infection. RESULTS: Microsporidial infection markedly activated the PI3K/Akt pathway in the cornea, as evidenced by increased phosphorylation of PI3K and Akt. Transcriptomic analysis revealed upregulation of inflammatory cytokines, including MMP9, IL-1β, and TNF-α, indicating activation of inflammation-related pathways. Histologic analysis further confirmed increased immune cell infiltration and stromal edema in infected corneas. Pretreatment with LY294002 prior to infection alleviated the clinical manifestations of MSK, including corneal opacity, and reduced corneal expression of inflammatory expression levels, suggesting a contributory role of PI3K/Akt pathway in the pathogenesis and inflammation of MSK. CONCLUSIONS: PI3K/Akt signaling is a critical driver of inflammation in MSK. Targeting this pathway may present a promising strategy for the management of MSK. Future studies should focus on developing ocular-optimized inhibitors of the PI3K/Akt pathway and evaluating their safety and efficacy for potential clinical application in MSK treatment.
引用
- Wei Y, Xu X, Peng Y, et al. PI3K/Akt Signaling as a Potential Therapeutic Target for Reducing Inflammation and Corneal Stromal Injury in Microsporidial Stromal Keratitis. Invest Ophthalmol Vis Sci. 2026. PMID: 42149030. doi:10.1167/iovs.67.5.42
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。